Kardium Attracts New Funding for Afib Treatment Debut

Kardium Inc. has secured $250 million in new funding to help finance the premiere of its Globe Pulsed Field System, an atrial fibrillation (AF) treatment.

The oversubscribed round was led by new investors including Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. Existing investors also participated, including funds and accounts advised by T. Rowe Price Associates, Inc., T. Rowe Price Investment Management, Inc., and Durable Capital Partners LP. The financing also includes an equity investment from a leading strategic investor.

“We are delighted to join Kardium as an investor,” said Aaron Schaechterle, portfolio manager at Janus Henderson Investors. “The Globe System is a disruptive innovation with exemplary clinical outcomes that has the potential to improve the lives of patients with atrial fibrillation. This is a pivotal moment in the evolution of AF treatment, as the field transitions toward pulsed field ablation, and we are proud to help support the introduction of Kardium’s technology to the market.”

The new funding will enable Kardium to pursue regulatory approvals for the Globe System, further expand its manufacturing facilities and production capacity, and establish a clinical support and commercial team for the Globe System’s expected commercial launch later this year. It will also enable Kardium to run further clinical research for additional applications and expanded indications for the Globe System.

Clinical data from the pivotal PULSAR clinical study of the Globe System demonstrated positive results, showing freedom from atrial arrhythmia at one year of 78% in paroxysmal AF patients, with 0% device-related primary safety events.ⁱ

“We’re thrilled to have secured this transformational financing with a world-class syndicate of investors,” Kardium CEO Kevin Chaplin said. “This funding enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energized by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation.”

The Globe Pulsed Field System consists of a catheter with a 122-electrode array and advanced software that enables rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium—all with a single catheter.

Founded in 2007, Kardium Inc. is a privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment. The Canadian company has worked with top medical advisors to develop the Globe System.

Reference
ⁱ A Multielectrode Spherical Array Pulsed Field Ablation System to Treat Paroxysmal Atrial Fibrillation: 1-Year Outcomes of the PULSAR IDE Trial. Oral presentation at HRS 2025 by Dr. Vivek Reddy (New York, USA).